| Biomarker ID | 494 |
| PMID | 19894759 |
| Year | 2009 |
| Biomarker | transglutaminase 2 isoform a; TPM1 protein; FTH1 protein; S100 calcium binding protein A9; splicing factor, arginine/ serine-rich 1 isoform 1; chromatin modifying protein 4B; |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated ratio in Localised PCA: transglutaminase 2 isoform a [2.03]; TPM1 protein [4.18]; FTH1 protein [2.28]; S100 calcium binding protein A9 [3.81]; splicing factor, arginine/ serine-rich 1 isoform 1 [2.07]; chromatin modifying protein 4B [2.16]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Localized PCa and BPH |
| Type of Biomarker | Diagnostic |
| Cohort | 17 cases of PCa who underwent radical prostatectomy and standard bilateral lymphadenectomy and 10 cases of benign prostatic hyperplasia (BPH) were collected. The PCa samples were divided into two groups of localized PCa (N ) 10) and LNM PCa (N ) 7) according to the postoperative pathological examinations of pelvic lymph nodes |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | 2-D DIGE coupled with MALDI-TOF/TOF MS |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | NA |